2023-07-20 15:25:20 ET
Shares of Atossa Therapeutics ( NASDAQ: ATOS ) traded higher Thursday after the oncology-focused biotech said that Canadian health regulators issued a "No Objection Letter" regarding its request to conduct a Phase 2 trial for a breast cancer therapy.
The decision by Health Canada allows the company to open trial sites and enroll patients for its EVANGELINE study in Canada.
The trial is currently underway in the U.S. for patients with Estrogen Receptor positive (ER+) or Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.
EVANGELINE is designed to evaluate Atossa’s ( ATOS ) lead candidate ( Z )-endoxifen with exemestane plus goserelin as a neoadjuvant treatment in about 175 patients in the U.S. and Canada.
Within weeks, the company expects to release data pertaining to the optimal dose for the treatment arm.
"Once the dose is confirmed, we expect the pace of enrollment to increase as we activate additional sites in the United States and Canada," CEO Steven Quay explained.
More on Atossa
- Atossa jumps 17% after update on mid-stage trial for breast cancer drug
- Atossa Therapeutics: Still Gets An 'Incomplete' Rating
For further details see:
Atossa gains as Canada greenlights breast cancer trial